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Abstract
Multiple epidemiologic studies show that adeno-associated virus (AAV) is negatively associated with cervical cancer (CX CA), a cancer
which is positively associated with human papillomavirus (HPV) infection. Mechanisms for this correlation may be by Rep78’s (AAV’s
major regulatory protein) ability to bind the HPV-16 p97 promoter DNA and inhibit transcription, to bind and interfere with the functions
of the E7 oncoprotein of HPV-16, and to bind a variety of HPV-important cellular transcription factors such as Sp1 and TBP. c-Jun is
another important cellular factor intimately linked to the HPV life cycle, as well as keratinocyte differentiation and skin development. Skin
is the natural host tissue for both HPV and AAV. In this article it is demonstrated that Rep78 directly interacts with c-Jun, both in vitro and
in vivo, as analyzed by Western blot, yeast two-hybrid cDNA, and electrophoretic mobility shift-supershift assay (EMSA supershift).
Addition of anti-Rep78 antibodies inhibited the EMSA supershift. Investigating the biological implications of this interaction, Rep78
inhibited the c-Jun-dependent c-jun promoter in transient and stable chloramphenicol acetyl-transferase (CAT) assays. Rep78 also inhibited
c-Jun-augmented c-jun promoter as well as the HPV-16 p97 promoter activity (also c-Jun regulated) in in vitro transcription assays in T47D
nuclear extracts. Finally, the Rep78–c-Jun interaction mapped to the amino-half of Rep78. The ability of Rep78 to interact with c-Jun and
down-regulate AP-1-dependent transcription suggests one more mechanism by which AAV may modulate the HPV life cycle and the
carcinogenesis process.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Adeno-associated virus (AAV) type 2 is a small non-
pathogenic DNA virus which, similar to human papilloma-
virus (HPV), is productive in stratified squamous epithelium
(Meyers et al., 1992, 2000, 2001), but otherwise requires
additional “helper” functions from adeno-, herpes-, or
papillomaviruses (Myers et al., 1980; Walz et al., 1997;
Weindler and Heilbronn, 1991). Keratinocyte differentia-
tion within the epithelium is needed for both AAV and HPV
productive replication. AAV and HPV are also known to
interact in the stratified squamous epithelium generated in
vitro with AAV having a dual effect (Meyers et al., 2001).
At low multiplicities of infection (m.o.i.) HPV DNA repli-
cation is increased, while at high m.o.i. HPV DNA replica-
tion is inhibited. It has been well documented that the
cellular transcription factor c-Jun is important for both ker-
atinocyte differentiation (Angel et al., 2001) as well as the
HPV life cycle (Cripe et al., 1990; Nurnberg et al., 1995;
Hubert et al., 1999). c-Jun is also involved in HPV-induced
oncogenic transformation of cells. The expression profile of
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c-Jun is positively correlated with expression levels of
E6/E7 oncoproteins of HPV (Kyo et al., 1997). Elevated
levels of c-Jun activity are important in advancing cell
through G1 phase of cell cycle as c-Jun can transactivate the
promotor of cyclin D1 (Bakiri et al., 2000). E7 of HPV
interacts with c-Jun and this leads to enhancement of AP-1
activity and may be a part of the mechanism by which HPV
transforms cells (Antinore et al., 1996).
AAV is known to possess oncosuppressive functions
against adenovirus (de la Maza and Carter, 1981; Ostrove et
al., 1981) and papillomaviruses (Hermonat, 1989, 1994a;
Hermonat et al., 1997; Horer et al., 1995; Zhan et al., 1999)
in tissue culture and epidemiologic studies (Mayor et al.,
1976; Georg-Fries et al., 1984; Coker et al., 2001; Smith et
al., 2001; Walz et al., 2002). This property has been attrib-
uted to AAV’s nonstructural major regulatory protein,
Rep78 (Hermonat, 1989, 1994; Horer et al., 1995; Zhan et
al., 1999). Rep78, the biggest of four rep proteins, plays a
crucial role in AAV replication, transcriptional regulation,
and integration (Hermonat et al., 1984; Labow et al., 1986;
Ni et al., 1994; Tratschin et al., 1984, 1986; Young et al.,
2000). Apart from these essential AAV functions, Rep78
has the ability to interfere with the expression of viral and
cellular oncogenes, including those of human papillomavi-
rus type 16 (Hermonat, 1991; Hermonat et al., 1996, 2000).
This is consistent with AAV’s known interactions with a
variety of transcription factors, including Sp1, TBP, E2F-1,
and PCN4 (Batchu et al., 2001; Hermonat et al., 1996, 1998;
Weger et al., 1999). The oncoproteins of HPV have the
ability to deregulate the function of essential cellular tumor
suppressor proteins such as p53 (Thomas et al., 1999), pRB
(Munger et al., 2001), and the recent studies of protective
activities of Rep78 against p53 degradation (Batchu et al.,
1999), arresting the cells in S-phase through ectopic accu-
mulation of active pRB (Saudan et al., 2000), and inhibition
of E2F-1 activity (Batchu et al., 2001) revealed some of the
underlying mechanisms of Rep78-mediated oncosuppres-
sion. Because of Rep78’s importance in the AAV life cycle,
its effects upon the HPV life cycle (both are epithelial-tropic
viruses) and HPV oncogenic transformation, and its ability
to affect keratinocyte differentiation, we investigated if the
Rep78 protein might bind to the c-Jun protein. In this article
we demonstrate that Rep78 can bind c-Jun both in vitro and
in vivo in yeast and that this association down-regulates
transcription from AP-1-dependent promoters.
Results
Rep78 binds c-Jun as demonstrated by Western blot
analysis and amino half of Rep78 is required for this
interaction
A Far Western blot was initially performed to inves-
tigate the possibility of Rep78 binding to c-Jun. The
c-Jun and MBP-Rep78 proteins were analyzed in Fig. 1A
by SDS–PAGE and are shown to be the expected sizes
with some breakdown products, particularly for MBP-
Rep78 (common to most preparations). For Far Western
blot analysis the MBP-Rep78, MBP, and c-Jun proteins
were PAGE or SDS–PAGE separated and electroblotted
onto membranes as indicated. In Fig. 1B identical PAGE
(non-denatured conditions) generated membranes were
probed with either the full-length MBP-Rep78 or the
amino-half deleted MBP-Bam-Rep (a deletion of about
243 amino acid residues at the amino end of Rep78). An
HRPO enzymatic assay was performed as described un-
der Materials and methods using anti-Rep antibody. As
can be seen in Fig. 1B MBP-Rep78 was able to bind to
membrane-bound MBP-Rep78 and to c-Jun, while MBP
was not recognized. In contrast, MBP-Bam-Rep was only
able to bind MBP-Rep78 and c-Jun was not recognized
by MBP-Bam-Rep. Fig. 1C shows a near identical exper-
iment in which the proteins to be Western blotted were
separated by SDS–PAGE (denatured conditions). As in
Fig. 1B, MBP-Rep78 recognized itself and c-Jun, while
MBP-Bam-Rep recognized only MBP-Rep78. These data
suggest that Rep78 has the ability to bind c-Jun. Further-
more, the inability of MBP-Bam-Rep78 to bind c-Jun
suggests that the amino-half of Rep78 is required for this
interaction. The same region of Rep78 is known to be
required for recognition of Sp1 (Hermonat et al., 1996).
Fig. 1. Characterization of the c-Jun and MBP-Rep78 proteins and analysis
of their interaction by Far Western blot assay. (A). One microgram of c-Jun
and MBP-Rep78 were analyzed by 10% SDS–PAGE. Marker lane con-
tained proteins of the indicated sizes in kDa. Expected sizes of MBP-Rep78
and c-Jun are 114 and 40 kDa, respectively. (B and C) One hundred
nanograms of MBP-Rep78, c-Jun, and MBP were electroblotted onto
nitrocellulose membrane after separating them by PAGE (B) and SDS–
PAGE (C) and probed with MBP-Rep78, MBP-Bam-Rep78 as described
under Materials and methods. Note that in both naive (PAGE) and dena-
tured (SDS–PAGE) conditions MBP-Rep78 recognizes itself as well as
c-Jun. However, the deletion Rep78 protein, MBP-Bam-Rep78, failed to
interact with c-Jun while it still could interact with itself.
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Rep78 binds c-Jun in vivo by yeast two-hybrid cDNA
analysis
To verify Rep78/c-Jun interaction in living cells, the
yeast two-hybrid cDNA assay was used. The plasmid con-
struct pBD-Rep78 fused the GAL4 DNA binding domain
ORF to the Rep78 ORF, while pAD-c-Jun fused the GAL4
transactivation domain and c-Jun ORF. Similar plasmids,
AD-T Ag and AD-E1A, were constructed containing the
SV40 large T antigen and adenovirus type 2 E1A in place of
c-Jun. These plasmids, either alone or in combination, were
transfected into yeast; the yeast cells were then double-
selected on plates lacking tryptophan and leucine. Cell ex-
tracts were prepared and resulting -galactosidase activity
was measured. Negative control transfections included BD-
Rep78AD-p53, BD-Rep78AD-LaminC, BDAD-T
Ag, BDAD-E1A, and BDAD-Jun (no interaction). Pos-
itive control transfections included BD-Rep78AD-Sp1,
BD-Rep78AD-TBP, BD-Rep78AD-T Ag, and BD-
Rep78AD-E1A. All of these protein combinations are
known to interact. The results are shown in Fig. 2. The
positive and negative controls gave results as expected.
Most importantly the combination of BD-Rep78AD-Jun
gave a strong signal, comparable to that of BD-Rep78AD-
TBP. These data strongly support the Western blot data,
suggesting that Rep78/c-Jun interaction can take place at
significant levels within the living cell.
Rep78 binds c-Jun in vitro as shown by EMSA supershift
analysis
As c-Jun is a DNA binding transcription factor, we
investigated if Rep78 might alter the c-Jun/DNA complex.
Rep78–c-Jun interaction might sterically inhibit the c-Jun–
DNA interaction or, alternatively, Rep78 might be added to
the complex. Such changes can be observed using the
EMSA assay. In Fig. 3 c-Jun is shown to bind and shift a
32P-labeled 24-base double-stranded DNA substrate (from
the human papillomavirus type 16 p97 promoter region)
containing the consensus c-Jun binding motif (Fig. 3, lane
5). This binding of c-Jun to its motif was specific as addition
of 50 molar excess of unlabeled DNA competitor dimin-
ished the strength of the shifted band (Fig. 3, lane 6). This
is in contrast to the addition of unlabeled DNA competitor
with a mutation within the c-Jun motif DNA (see Materials
and methods), which had no effect (Fig. 3, lane 7). MBP-
Rep78 alone was unable to bind the jun-motif-DNA (Fig. 3,
lane 9). However, the addition of MBP-Rep78, along with
c-Jun, resulted in the formation of a new higher and stronger
complex above the c-Jun–DNA complex, suggesting c-Jun–
Rep78 interaction (Fig. 3, lane 4). The specificity of
Rep78–c-Jun–DNA complex formation was further chal-
lenged with anti-Rep78 antibody. It was found that the
addition of these anti-Rep antibodies inhibited the formation
of Rep78–c-Jun–DNA complexes in a dose-dependent
manner (Fig. 3, lanes 1–3). The addition of MBP alone had
no influence on c-Jun–DNA complex formation (Fig. 3, lane
Fig. 3. Rep78 binds DNA bound-c-Jun by EMSA super-shift analysis.
EMSA showing the in vitro interaction of MBP-Rep78 (0.5 g) with c-Jun
(0.3 g). The c-Jun-Rep78 super shift was clear only when the gel was run
for a long time, thus the free probe was run off the gel. Increasing the gel
concentration compromised the super shift. Therefore, two gels with the
same set of samples were run at the same time; one ran for a short time to
see the free probe and another for super shift, both are shown, top and
bottom. c-Jun binds to the AP-1-motif oligonucleotide and the strength of
the shifted band is unaffected in presence of cold, mutant competitor but is
affected in presence of cold, AP-1 specific competitor. Note that a new
complex containing c-Jun/Rep78 and DNA was formed above the c-Jun-
DNA complex when MBP-Rep78 was added. Addition of MBP alone had
no effect. Anti-Rep78 antibodies decreased the strength of this new com-
plex in a dose-dependent manner.
Fig. 2. Rep78 binds c-Jun by yeast GAL4-two hybrid cDNA analysis.
Histogram showing the quantitated -galactose activities of yeast extracts
obtained after transfecting yeast with the indicated plasmid constructs.
Note that Rep78 interaction with c-Jun is quite strong, comparable with
Rep78/TBP and Rep78/Sp1 interaction.
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8). These data further support the Western blot and yeast
two-hybrid cDNA analyses, all indicating Rep78 interaction
with c-Jun. These data also suggest that c-Jun can bind both
its DNA substrate and Rep78 simultaneously.
Rep78 inhibits transcription from the c-jun promoter by
CAT assay
To investigate the biological implications of Rep78–c-
Jun interaction, transient transfection assays were per-
formed to study chloramphenicol acetyl (CoA) transferase
product expression from a c-Jun-dependent promoter. The
c-jun proto-oncogene promoter, itself, is c-Jun-responsive
(Angel et al., 1988). In a transient assay system SW13 cells
were calcium phosphate transfected with 4 g of c-jun
promoter-CAT plus 8 g d110–37 (Rep78) or pKEX-
Rep78 (Rep78) (Fig. 4A and B). The murine osteosarco-
mavirus long terminal repeat (MSV-LTR) was also used as
a largely Rep78-insensitive control (very few of such pro-
moters have been identified, Hermonat et al., 1996). Anal-
ysis of the MSV-LTR promoter sequence indicates that
there are no c-Jun recognition motifs, consensus or closely
related (5 of 6), present within the promoter. A quantifica-
tion of the results is shown in Fig. 4A, and a representative
CAT assay (of three) is shown in Fig. 4B. As can be seen in
Fig. 4A and B transfection of Rep78 expression plasmid
pKEX-Rep78 decreased c-Jun driven CAT activity by 82%,
while the MSV-LTR was inhibited by 22%. The positive
and negative control plasmids (pSV2-CAT and pA10-CAT,
respectively) gave the expected CAT activities. It should
also be noted that pKEX-Rep78 expresses only the Rep78
protein and not the smaller, related Rep68, Rep52, or Rep40
(Horer et al., 1995). In a second CAT assay, designed to
study Rep78 dosage effects, SW13 cells were calcium trans-
fected with 4 g of c-jun promoter-CAT plasmid plus
increased amounts of pKEX-Rep78 plasmids (Fig. 4C). As
can be seen in Fig. 4C transfection of increasing amounts of
KEX-Rep78 resulted in a dose-dependent decrease of c-Jun
driven CAT activity.
In a stable CAT assay, HeLa cells were calcium phos-
phate transfected with 2 g of c-jun promoter-CAT plasmid
plus 2 g of either pSV2-Neo (Rep78) or d152-91/Neo
(Rep78). Additional proto-oncogene promoter-CAT plas-
mid constructs were used as controls, including c-fos, c-
myc, c-H-ras. The cells were G418 selected for 3 weeks and
the G418-resistant colonies were pooled, and lysates were
made for CAT enzyme activity. As can be seen in Fig. 4D
cotransfection of the c-jun promoter-CAT plasmid with
d152-91/Neo (Rep78) resulted in down-regulation of
CAT activity compared to cotransfection with pSV2-CAT
(Rep78). These data further support the transient CAT
assay finding that Rep78 inhibits c-Jun-dependent promoter
activity. In the controls Rep78 inhibited CAT activity from
the c-fos, c-myc, c-H-ras proto-oncogene promoters as ex-
pected (Hermonat, 1991, 1994b).
Fig. 4. Rep78 inhibits c-Jun-dependent transcription in transient and
stable CAT assays. (A and B) Promoter-specific inhibition by MBP-
Rep78. SW13 cells were transfected with c-Jun-CAT or murine osteo-
sarcoma virus LTR-CAT plasmid and different amounts of dl10 –
37(Rep78) or pKEX-Rep78(Rep78). Extracts were prepared from
the transfected cells, equalized for the protein amount and assayed for
CAT activity. A quantification of the results is shown in (A) and a
representative experiment (of three) is shown in (B). Note that the c-jun
promoter was sensitive to Rep78 inhibition, while the MSV-LTR pro-
moter was largely insensitive. (C) Dosage-dependent inhibition of c-
Jun-dependent promoter by Rep78 in a transient assay. SW13 cells were
transfected with c-jun-CAT plasmid (4 g) and different amounts of
pKEX-Rep78(Rep78) (1, 3, and 10 g). Extracts were prepared from
the transfected cells, equalized for the protein amount, and assayed for
CAT activity. Note that with increasing amounts of pKEX-Rep78
increased inhibition of CAT expression resulted. (D) Inhibition of c-jun
promoter activity by Rep78 in a stable CAT assay. HeLa cells were
transfected with c-jun-CAT, c-fos-CAT, c-ras-CAT or c-myc-CAT plus
pSV2-Neo (Rep78) or dl52-91-Neo (Rep78), selected for G418
resistance, and extracts assayed for CAT activity. Note that in presence
of Rep78, CAT activity from c-jun-CAT is diminished. Also note that
the CAT activity from control plasmid constructs was decreased.
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Rep78 inhibits c-Jun augmented transcription in vitro in
nuclear extracts
To further investigate the biological significance of
Rep78/c-Jun interaction we assayed these proteins in in
vitro transcription assays in T47D nuclear extracts. A c-jun-
promoter DNA fragment/transcription substrate was gener-
ated by PCR amplification which contained the c-jun proto-
oncogene promoter and the upstream sequences of CAT as
described under Materials and methods. The substrate pro-
moter DNA, the c-Jun, MBP-Rep78, MBP proteins and
[32P]CTP were added to nuclear extracts as indicated and
the products were analyzed by UREA–PAGE as shown in
Fig. 5A. As seen the addition of c-Jun protein increased
transcription from the c-Jun promoter, and when MBP-
Rep78 was added along with c-Jun, c-Jun-dependent tran-
scription was inhibited. In three experiments, under the
standardized conditions of 1.2 g of c-Jun added compared
to 1.2 g of c-Jun plus 2.0 g of MBP-Rep78 added (a
stochiometric ratio of 1-to-1), transcription from the c-jun
promoter was inhibited by 69.5  15.5%. In contrast, the
addition of MBP protein had little or no affect on c-Jun-
augmented transcription. The addition of MBP-Rep78,
alone resulted in undetectable transcription. The responsive-
ness of the c-jun promoter was further analyzed to verify
that we were observing c-Jun-dependent transcription from
the c-jun promoter. As can be seen in Fig. 5B the level of
CAT transcripts was increased in a dosage-dependent fash-
ion with the addition of further c-Jun protein. Thus, even
though the nuclear extracts had an endogenous level of
c-Jun and could carry out a basal level of transcription (Fig.
5B, lane 1), we could augment the level of c-Jun-dependent
transcription by the addition of additional c-Jun protein
(Fig. 5B, lanes 2–4). A third type of nuclear extract tran-
scription experiment (Fig. 5C) was carried out in which the
level of added c-Jun protein was kept constant, but in which
increasing amounts of MBP-Rep78 were added. As can be
seen the addition of MBP-Rep78 protein inhibited the c-Jun
augmented transcription in a dosage-dependent fashion.
A second DNA fragment/transcription substrate was
generated by PCR amplification which contained the
HPV-16 p97 promoter and the upstream sequences of CAT
as described under Materials and methods. This promoter is
also known to be c-Jun responsive (Cripe et al., 1990;
Hubert et al., 1999; Nurnberg et al., 1995). The p97-CAT
substrate promoter DNA, the c-Jun, MBP-Rep78, MBP, and
GST proteins, and [32P]CTP were added as indicated to
nuclear extracts and the products were analyzed by UREA–
PAGE as shown in Fig. 6A. As can be seen the HPV-16 p97
promoter, as expected, was also found to be c-Jun respon-
sive in nuclear extracts. Furthermore, the addition of MBP-
Rep78 inhibited this c-Jun-augmented transcription. In three
experiments, under the standardized conditions of 1.2 g of
c-Jun added compared to 1.2 g of c-Jun plus 2.0 g of
MBP-Rep78 added (a stochiometric ratio of 1-to-1), tran-
scription from the p97 promoter was inhibited by 72.8 
11.5%. In contrast, MBP and GST had no affect. Finally, the
addition of the anti-Rep antibody abrogated inhibition by
MBP-Rep78 in a dose-dependent manner. A second type of
experiment (Fig. 6B) demonstrated that the p97 promoter
was also transactivated in a dose-dependent manner by the
increasing amounts of c-Jun protein. Finally, in Fig. 6C it is
shown that increasing amounts of MBP-Rep78 inhibited
p97-Jun transactivated transcription (constant c-Jun) in a
dose-dependent manner.
Discussion
The present study demonstrates that the Rep78 and c-Jun
proteins interact and that this interaction causes a down-
regulation of c-Jun-dependent transcription. Both AAV and
HPV are cutaneous tissue-tropic viruses, productively rep-
Fig. 5. Rep78 inhibits c-Jun-dependent transcription from the c-jun proto-
oncogene promoter in nuclear extracts. (A) Transactivation of the c-jun
gene promoter by c-Jun protein and inhibition by MBP-Rep78. c-jun-CAT
DNA and MBP (1 g), MBP-Rep78 (1 g), or c-Jun protein (1 g) were
added to T47D nuclear extracts as indicated and as described under Ma-
terials and methods. The radiolabeled products were then analyzed by
UREA–PAGE. Note that the addition of c-Jun resulted in higher amounts
of c-jun RNA (496 nt.). Also note that the addition of MBP-Rep78 to c-Jun
augmented extracts resulted in an inhibition of the c-jun-dependent tran-
scription, whereas the addition of MBP did not affect the level of c-jun
RNA. Finally, addition of MBP-Rep78 to the extract, in the absence of
c-Jun, resulted in extremely low c-jun RNA. (B) Dose-dependent transac-
tivation of the c-jun gene promoter by c-Jun protein. c-jun-CAT DNA and
increasing amounts of c-Jun protein (0.6, 1.2, 1.8 g) were added to T47D
nuclear extracts as described under Materials and Methods, and the radio-
labeled products were analyzed by UREA–PAGE. It can be seen that
increasing amounts of c-Jun resulted in higher amounts of c-Jun RNA (496
nt.). (C) Dose-dependent inhibition of c-Jun protein-augmented transcrip-
tion from the c-jun gene promoter by MBP-Rep78. This experiment was
similar to (A) and (B) except that 1.2 g of c-Jun protein was added to the
nuclear extracts, as well as increasing amounts of MBP-Rep78 (0.5, 1.0,
2.0 g). Note that increasing amounts of MBP-Rep78 resulted in lower
amounts of c-jun RNA.
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licating in differentiating keratinocytes. The importance of
c-Jun functions for keratinocyte differentiation, the HPV
life cycle, and HPV-dependent oncogenic transformation
are evident from many previous studies (Angel et al., 2001;
Cripe et al., 1990; Hubert et al., 1999). The expression of
the E6 and E7 proteins of HPV is positively regulated by
c-Jun (Kyo et al., 1997). c-Jun is also at a control point in
the cell cycle and that manipulation and modulation of c-Jun
by viral proteins is a point of removal of cell growth inhi-
bition. E7 of HPV-16 targets c-Jun and up-regulates its
activity, which is needed for deregulating the cell-cycle
controlling point. The interaction of the E7 with c-Jun could
be an important factor along with E7 interaction with pRB,
as the latter interaction alone is not sufficient enough for
transformation (Fogel and Risu, 1998). The observation that
c-Jun deletion mutants, that are able to interact with E7 but
impaired in their transactivation abilities, are unable to
mediate transformation showed the importance of c-Jun
mediation (Antinore et al., 1996). Similarly, when c-Jun
protein levels were brought down using antisense oligonu-
cleotides which targeted c-Jun RNA, the transformed phe-
notype was abolished in HPV-transformed cells (Chen et
al., 1994). Now, knowing the importance of c-Jun in the
HPV life cycle, Rep78 interaction with c-Jun might have
many mechanistic implications.
It has been reported that the composition of AP-1 com-
plex differs between normal and HPV transformed cells. In
normal cells c-Jun pairs predominantly with Fra-1, whereas
in HPV transformed HeLa cells c-Fos levels are increased
over Fra-1. Thus, c-Fos might be the favored partner of
c-Jun and this change in composition of the AP-1 complex
might be important for HPV-induced transformation (Soto
et al., 1999). It is interesting to note that c-Jun is able to bind
DNA and the Rep78 protein simultaneously (Fig. 4). This is
true of course for the c-Jun/c-Fos heterodimer AP-1, and
related c-Jun-based complexes. In this study we also ob-
served that in presence of Rep78, c-Jun’s DNA binding
efficiency was also increased (Fig. 2), in a similar manner as
c-Fos (Halazonetis et al., 1988). However, unlike the inter-
action of c-Fos with c-Jun, the interaction of Rep78 with
c-Jun affected the transactivation capabilities of c-Jun in a
negative manner. This suggests that Rep78 may alter c-Jun-
dependent transcription by inhibiting c-Jun binding to
needed transcriptional partners/cofactors such as c-Fos, pos-
sibly through steric inhibition. Thus the c-Jun/Rep78 com-
plex might be viewed under this hypothesis as a dominant-
negative AP-1 mimic. An alternative hypothesis is that the
c-Jun/Rep78 complex may attract a new set of transcription
factor interactions entirely different from the traditional
AP-1 complex. This new set of transcription factors might
have a much different signal transduction outcome. Instead
of HPV p97 promoter- or c-jun-promoter-c-Jun-dependent
transcriptional up-regulation and cell-cycle progression, the
end result would be down-regulation and cell-cycle arrest.
Regarding the HPV-16 p97 promoter, yet a third alternative
might be that the c-Jun/Rep78 complex, bound at c-Jun’s
normal binding sites, might interact through Rep78–Rep78
interaction with adjacent downstream Rep78 homocom-
plexes bound within HPV-16 p97 promoter (Zhan et al.,
1999). Such DNA-Rep78/Rep78-DNA supercomplexes
have been shown to exist (Weitzman et al., 1994). Finally,
a fourth mechanism of inhibition, which seems well sub-
stantiated, might be through the direct down-regulation of
the c-jun gene itself. With less c-Jun protein being ex-
pressed, less c-Jun/AP-1-dependent transcription will result.
This should also inhibit progression through the cell cycle.
With the likelihood that Rep78 interferes with both c-Jun
protein activity and c-jun proto-oncogene expression, we
can predict a possible bimodal affect. First, Rep78 can
immediately bind and alter c-Jun protein complexes already
present within the cell. Second, the extended temporal af-
Fig. 6. Rep78 inhibits c-Jun-dependent transcription from the HPV-16 p97
promoter in nuclear extracts. (A) Specific transactivation and inhibition of
the p97 promoter by c-Jun and Rep78 proteins, respectively. p97-CAT
DNA and proteins c-Jun (1 g), MBP-Rep78 (1 g), MBP (1 g), GST (1
g), or anti-Rep antibody were added to T47D nuclear extracts, as indi-
cated and as described under Materials and methods, and the radiolabeled
products were analyzed by UREA–PAGE. Note that c-Jun increased tran-
scription and Rep78 inhibited c-Jun-mediated transcription as indicated by
the 350-base band signal. Note that the addition of GST or MBP had no
effect upon c-Jun-dependent p97 activity. Also note that the addition of
anti-Rep antibody abrogated MBP-Rep78 inhibition of p97 in a dose-
dependent manner. (B) Transactivation of the p97 promoter by c-Jun
protein. p97-CAT DNA and increasing amounts of c-Jun protein (0.6, 1.2,
2.4 g) were added to T47D breast cancer cell nuclear extracts as described
under Materials and methods and the radiolabeled products were analyzed
by UREA–PAGE. Note that increasing amounts of c-Jun resulted in higher
levels of p97 RNA (350 bp). (C) Rep78 inhibition of c-Jun protein-
augmented transcription from the p97 promoter. This representative exper-
iment was similar to (A) except that 1.2 g of c-Jun protein was added to
the nuclear extracts, as well as increasing amounts of MBP-Rep78 (0.5,
1.0, 2.0 g). Note that increasing amounts of MBP-Rep78 resulted in lower
amounts of p97 RNA.
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fects of Rep78 would be the overall lowering of c-Jun
concentrations within the cell. In any case, the present study
does not address the question of whether Rep78 may sup-
plant c-Fos. This question will soon be addressed in planned
experiments. Also we have not addressed whether Rep78
can disrupt c-Jun-E7 heterodimers. However, by virtue of
its ability to interact with both partners Rep78 might very
well affect E7/c-Jun complex formation.
Another aspect that needs to be discussed is the possible
importance of Rep78/c-Jun interaction with respect to the
AAV life cycle. It is worth considering that AAV is also
epithelial tropic virus and can replicate autonomously in
differentiating keratinocytes without helper functions from
HPV or any other virus (Meyers et al., 2000). As c-Jun is
clearly involved in keratinocyte differentiation, it can be
extrapolated that c-Jun might be a relevant transcription
factor for AAV autonomous replication as it is for HPV.
This hypothesis can be tested by using wild-type and mutant
c-Jun proteins. In summary, Rep78, the main regulatory
protein of AAV, exerts antiproliferative actions against
HPV and this is brought about in multiple ways. Here we
have demonstrated Rep78/c-Jun interaction as yet another
possible mechanism of controlling HPV-induced transfor-
mation by AAV.
Materials and methods
Cells, plasmids, proteins
Human HeLa and SW13 cells were grown in DMEM
with 7% fetal bovine serum, 100 g/ml penicillin, and 100
g/ml streptomycin. The plasmids pSV2-Neo, d152-92/
Neo, MBP-Bam-Rep (previously known as Bam-Rep), AD-
p53, AD-pLaminC, AD-TBP, AD-Sp1, BD, BD-Rep78, the
c-Jun-dependent plasmid c-jun promoter-CAT plasmid
(previously known as p-132/170 Jun-CAT), LTR-CAT,
p97-CAT, and the AAV plasmids dl10-37, dl52-91/Neo,
and pKEX-Rep78 have been previously described (Batchu
et al., 1995 ; Hermonat, 1994b; Hermonat et al., 1996, 1998;
Hermonat and Muzyczka, 1984; Horer et al., 1995; Zhan et
al., 1999). AD-Jun, AD-T Ag, AD-Ad E1A were con-
structed by similar technique to that of AD-TBP (Hermonat
et al., 1998). MBP-Rep78 construction, MBP, MBP-Rep78
protein production, and purification was described else-
where (Batchu et al., 1995). c-Jun protein was obtained
from Promega (Madison, WI).
Yeast Gal4 two-hybrid cDNA analysis
Basic reagents and protocols for this assay were procured
from the HybriZap two-hybrid cDNA giga pack cloning kit
(Stratagene, La Jolla, CA). Construction of plasmids pBD-
Rep78, pAD-SP1, pAD-p53, and pAD-laminC was de-
scribed elsewhere (Hermonat et al., 1998, 2000). Plasmids
AD-Jun, AD-T Ag, and AD-E1A were constructed by clon-
ing the c-Jun, SV40 large T antigen, and adenovirus type 2
E1A open reading frames (ORF), respectively, in-frame
with the Gal4 transactivation domain in the plasmid pGal4-
AD. Yeast strains YRG-2 were transformed with the plas-
mid constructs using lithium acetate method and trans-
formed yeast clones were selected on medium lacking
tryptophan and leucine. -Galactosidase activity was quan-
titated from the transformed clones as described (Hermonat
et al., 2000).
Electrophoretic mobility shift assay (EMSA)
For EMSA analysis a full complementary double-
stranded oligonucleotide substrate was designed from p97
promoter of HPV-16 (nt 7621 to 7644), which contained an
AP-1 consensus sequence, TGAGTCA. A mutated version
of this substrate was also designed in which the AP-1
consensus sequence was altered to ATATTTA. The binding
reactions were performed in a total of 20 l as described
previously (Zhan et al., 1999). Briefly, 1 ng of 32P-labeled
DNA substrate was incubated with c-Jun or MBP-Rep78 or
both as per the experimental need. When indicated, poly-
clonal anti-Rep antibody (provided by James Trempe) was
preincubated with MBP-Rep78 at room temperature for 15
min before addition of c-Jun. For competitive experiments,
50 molar excess of unlabeled AP-1-specific or nonspecific
oligos were preincubated with c-Jun for 15 min at room
temperature before adding the labeled oligo. The protein–
protein/DNA complexes were analyzed on a 4% polyacryl-
amide gel with 5% glycerol under low ionic conditions
(0.25 TBE). Gels were then dried and exposed with an
intensifying screen at 80°C.
Western blot analysis
MBP-Rep78, c-Jun, and MBP were separated by either
SDS–PAGE or PAGE and electroblotted onto a nitrocellu-
lose membrane. The protein blots were incubated with un-
labeled MBP-Bam-Rep (10 g/ml) or MBP-Rep78 (10 g/
ml) after a BSA blocking step. Blots were probed by
incubating with 1:200 dilution of polyclonal anti-Rep rabbit
antibody for 30 min at room temperature with constant
agitation. The blots were then subjected to three washings
for 10 min each with constant agitation. For enzymatic
probing, the blots were incubated with 1:10,000 dilution of
rabbit antibodies conjugated to HRPO for 30 min at room
temperature with agitation. After extensive washings, blots
were incubated in peroxidase enzymatic assay solution con-
sisting of 5 mg 4-chloraphthol substrate and 10 l H2O2.
After the appearance of the bands, the blot was thoroughly
rinsed with water and dried (Hermonat et al., 1996).
Transient and stable CAT assays
Transient CAT assays were carried out in SW13 cells
using calcium phosphate transfection method (Stratagene
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Transfection Kit as per manufacturer’s instructions). SW13
cells were transfected with 4 g of c-jun-CAT plus different
amounts, as indicated, of dl10-37 (does not express Rep78)
or pKEX-Rep78 (expresses Rep78). pSV2-CAT and pA10-
CAT were the positive and negative controls, respectively.
Forty-eight hours after transfection, cell extracts were pre-
pared, equalized for protein content, and assayed for CAT
activity as described previously (Hermonat et al., 1996). For
stable CAT assays, HeLa cells were calcium phosphate
transfected with 2 g of a CAT expression plasmid (either
c-jun-CAT, c-ras-CAT, c-myc-CAT, or c-fos-CAT) plus 2
g of a Neo expression plasmid (either pSV2-Neo
[Rep78] or dl52-91/Neo [Rep78]). Selection was done
on 800 g/ml of G418. Extracts were made from the resis-
tant cells (20–40 colonies each) 4 weeks after G418 selec-
tion, equalized for protein content, and assayed for CAT
activity as described (Hermonat et al., 1996).
In vitro transcription in nuclear extracts
A c-jun-CAT DNA fragment (628 bp), obtained by
performing PCR on plasmid 132/170 Jun-CAT using
primers (5 GCCTCTTCGCTATTA CGCCAGTCG 3 and
5 CATATCACCAGCTCACCGTC 3), and a p97-CAT
DNA fragment (1.2 kb) generated by PCR using the primers
and the template described earlier (Zhan et al., 1999), were
used as templates in in vitro transcription analysis. The
reactions were carried out at 30°C for 1 h in a total of 25 l
containing 15 g of T-47D nuclear extract (Geneka Corp.,
Montreal, Canada; HPV negative breast ductal carcinoma)
as described earlier (Zhan et al., 1999). The reactions were
terminated by adding 175 l of stop mix containing 0.3 M
Tris–HCl (pH 7.9), 0.3 M sodium acetate, 0.5% SDS, 2 mM
EDTA, and 3 g/ml tRNA. The mixture was then extracted
with phenol:chloroform:isoamyl alcohol (25:24:1) and the
RNA was precipitated by ethanol. The RNA was dissolved
in 10 l loading buffer (98% formamide, 10 mM EDTA,
and 0.1% bromphenol blue) and analyzed on 6% acryl-
amide, 7 M urea, 1 TBE gel. The gel was dried and
exposed to X-ray film with an intensifying screen at80°C.
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